Comparative anti-psoriatic efficacy studies of clobetasol loaded chitin nanogel and marketed cream.
In the present study chitin nanogel loaded with anti-psoriatic drug clobetasol was developed (CLCNG) for its topical delivery in psoriasis. CLCNG had the particle size of 132±14nm, with gel like consistency, stability in refrigerator, having higher drug release properties at acidic pH. CLCNG exhibited significant toxicity towards HaCaT and THP-1cell lines by MTT assay. The uptake of nanogel by HaCaT cell lines was confirmed by fluorescent microscopy. CLCNG at 0.35mg/ml exhibited significant anti-inflammatory activity with an average of 65% and 70% inhibition in COX and LOX activities expressed in THP-1 cells. In vitro skin permeation studies revealed the increased transdermal flux with fragmented stratum corneum and loosened epidermal layers in CLCNG treated samples, compared with control drug solution. The in vivo anti-psoriatic studies done on imiquimod model confirmed the potential benefits of the nanogel for the topical delivery of clobetasol in psoriasis.
Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Amrita University, Kochi 682041, India.
Rajitha
R
Panonnummal
Amrita Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Amrita University, Kochi 682041, India.
R
R
Jayakumar
Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Amrita University, Kochi 682041, India. Electronic address: sabitham@aims.amrita.edu.
M
M
Sabitha
D000279:Administration, Cutaneous; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000378:metabolism; D002460:Cell Line; D002686:Chitin / Q000008:administration & dosage* / Q000378:metabolism; D002990:Clobetasol / Q000008:administration & dosage* / Q000378:metabolism; D004337:Drug Carriers / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D000080385:Nanogels; D009924:Organ Culture Techniques; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000378:metabolism; D011094:Polyethyleneimine / Q000008:administration & dosage* / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012869:Skin Absorption / Q000187:drug effects / Q000502:physiology; D063465:Skin Cream / Q000008:administration & dosage* / Q000378:metabolism; D013552:Swine
D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D000080385:Nanogels; C413692:polyethylene glycol polyethyleneimine nanogel; D002686:Chitin; D011092:Polyethylene Glycols; D011094:Polyethyleneimine; D002990:Clobetasol
Anti-inflammatory; Clobetasol; Imiquimod; Nanogel; Psoriasis